• OPEN AN ACCOUNT
Indian Indices
Sensex
74,729.27 413.66
( 0.56%)
Global Indices
Nasdaq
52,025.19 -173.50
(-0.33%)
Dow Jones
7,682.22 -82.84
(-1.07%)
Hang Seng
65,489.63 1,063.68
(1.65%)
Nikkei 225
10,879.96 39.61
(0.37%)
Forex
USD-INR
94.85 -0.23
(-0.24%)
EUR-INR
106.35 0.11
(0.11%)
GBP-INR
125.73 -0.01
(-0.01%)
JPY-INR
0.60 0.00
(0.07%)

EQUITY - MARKET SCREENER

Sun Pharmaceutical Industries Ltd
Industry :  Pharmaceuticals - Indian - Bulk Drugs & Formln
BSE Code
ISIN Demat
Book Value()
524715
INE044A01036
93.2373503
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
SUNPHARMA
132.63
422282.95
EPS(TTM)
Face Value()
Div & Yield %
13.27
1
0.91
 

Schneider Electric Infrastructure slumps after dismal Q1 performance
Aug 17,2026

The company stated that the profitability was impacted by volatility of commodity prices, lag in passing on higher input costs, and by a relatively lower operating leverage.

Revenue rose by 4.8% year-on-year (YoY) to Rs 651.4 crore during the period under review. The topline growth was moderate due to project execution timelines and the phased conversion of recent order wins into sales.

EBITDA fell by 44.4% YoY to Rs 41 crore and EBITDA margin contracted by 550 basis points to 6.3% in the June'26 quarter.

Profit before tax in Q1 FY27 stood at Rs 17 crore, up by 69.6% from Rs 55.9 crore in Q1 FY26.

The company's order intake for Q1 FY27 was Rs 915 crore (up 0.5% YoY) as emerging segments like data centres and semiconductors witnessed strong demand.

Order backlog as on 30 June 2026 was Rs 2,169 crore, up 32.7% YoY.

Schneider Electric Infrastructure specializes in manufacturing, designing, constructing, and servicing advanced products and systems for electricity networks.